Fig. 4: Comparison of antibody and T cell responses in patients with cancer.
a, S1-reactive antibody titers in patients with leukemia (n = 11), myeloma (n = 4) and lymphoma (n = 6). b, NAb titers in patients with leukemia (n = 10), myeloma (n = 4) and lymphoma (n = 6). c, CD4+ and CD8+ cells T cells in patients with leukemia (n = 10), myeloma (n = 4) and lymphoma (n = 6). The stimulation index was calculated by dividing the percentage of CD4+CD137+OX40+ (CD4+) and CD8+CD137+CD69+ (CD8+) T cells in the stimulated sample by the percentage of positive cells in the NC. Significance was tested by Kruskal–Wallis test, where P < 0.05 was considered significant. d, S1-reactive antibody titers in patients with hematological malignancy receiving anti-CD20 treatment (n = 6) versus other SACT (n = 15). e, NAb titers in patients with hematological malignancy receiving anti-CD20 treatment (n = 6) versus other SACT (n = 15). Significance was tested by two-sided Wilcoxon–Mann–Whitney U-test, where P < 0.05 was considered significant. f, Comparison of CD4+/CD8+ T cells between patients with hematological malignancies on anti-CD20 therapy (n = 5, administered within 6 months) and not on anti-CD20 therapy (n = 15). Significance was tested by two-sided Wilcoxon–Mann–Whitney U-test, where P < 0.05 was considered significant. g, CD4+ and CD8+ cells T cells in patients with solid malignancies (n = 81) by cancer subtype. Boxes indicate 25th and 75th percentiles, the line indicates the median and whiskers indicate 1.5 × IQR. Dots represent individual patient samples. Dotted lines and gray boxes denote the limit of detection. Significance was tested by Kruskal–Wallis test, where P < 0.05 was considered significant.
